Johnson & Johnson
HealthcareNYSE:JNJ · New York Stock Exchange
+$1.71 today
Vol 2.90M · Avg 7.84M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$96.4B of revenue converted into $21.0B of net income for the selected period. Gross margin is 69.1% and net margin is 21.8%, showing how much revenue survives after costs and taxes. EPS is $8.65, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.2B +6.0% | $88.8B +4.3% | $85.2B +6.5% | $80.0B +1.6% | $78.7B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $25.6B -6.7% | $27.5B +3.5% | $26.6B +8.0% | $24.6B +5.1% | $23.4B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $68.6B +11.7% | $61.4B +4.7% | $58.6B +5.8% | $55.4B +0.1% | $55.3B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 72.8% +3.7pp | 69.1% +0.3pp | 68.8% -0.4pp | 69.3% -1.0pp | 70.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $14.7B -14.9% | $17.2B +14.2% | $15.1B +6.7% | $14.1B -1.0% | $14.3B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $23.7B +7.8% | $22.0B +9.2% | $20.1B -0.7% | $20.2B +0.6% | $20.1B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $43.0B +9.6% | $39.2B +11.4% | $35.2B +2.4% | $34.4B -0.0% | $34.4B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $7.5B +2.2% | $7.3B -2.0% | $7.5B +7.4% | $7.0B -5.7% | $7.4B | $374.2M | $1.2B | $631.8M |
| EBITDA | $41.1B +65.7% | $24.8B +6.3% | $23.3B -12.3% | $26.6B -0.5% | $26.8B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 43.6% +15.7pp | 27.9% +0.5pp | 27.4% -5.9pp | 33.3% -0.7pp | 34.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | $25.6B +15.6% | $22.1B -5.4% | $23.4B +11.4% | $21.0B +0.3% | $20.9B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 27.2% +2.2pp | 24.9% -2.6pp | 27.5% +1.2pp | 26.3% -0.3pp | 26.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.1B -20.7% | $1.3B +5.6% | $1.3B +157.3% | $490.0M +824.5% | $53.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $971.0M +28.6% | $755.0M -2.2% | $772.0M +179.7% | $276.0M +50.8% | $183.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $7.0B +227.9% | -$5.5B +34.6% | -$8.3B -404.7% | -$1.7B +6.3% | -$1.8B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $32.6B +95.2% | $16.7B +10.8% | $15.1B -22.2% | $19.4B +0.9% | $19.2B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 34.6% +15.8pp | 18.8% +1.1pp | 17.7% -6.5pp | 24.2% -0.2pp | 24.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $5.8B +120.4% | $2.6B +51.0% | $1.7B -41.9% | $3.0B +117.1% | $1.4B | $1.3B | -$1.6B | $745.2M |
| Net Income | $26.8B +90.6% | $14.1B -60.0% | $35.2B +95.9% | $17.9B -14.1% | $20.9B | $4.9B | $4.8B | $4.7B |
| Net Margin | 28.5% +12.6pp | 15.8% -25.4pp | 41.3% +18.9pp | 22.4% -4.1pp | 26.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $11 +88.9% | $6 -57.9% | $14 +103.2% | $7 -13.9% | $8 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $11 +90.5% | $6 -57.8% | $14 +103.9% | $7 -13.8% | $8 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $2.4B +0.9% | $2.4B -5.0% | $2.5B -3.1% | $2.6B -0.6% | $2.6B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $2.4B +0.0% | $2.4B -5.1% | $2.6B -3.9% | $2.7B -0.4% | $2.7B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
AbbVie Inc.
NYSE:ABBV
$401.42B
UnitedHealth Group Incorporated
NYSE:UNH
$370.46B
Merck & Co., Inc.
NYSE:MRK
$296.43B
Novartis AG
NYSE:NVS
$292.78B
AstraZeneca PLC
NYSE:AZN
$278.77B
Novo Nordisk A/S
NYSE:NVO
$196.35B
Amgen Inc.
NASDAQ:AMGN
$191.26B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.54B
Pfizer Inc.
NYSE:PFE
$149.33B
Sanofi
NASDAQ:SNY
$106.53B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does JNJ generate?
Johnson & Johnson (JNJ) reported $94.19B of revenue in fiscal 2025.
Is JNJ profitable?
Johnson & Johnson (JNJ) reported $26.80B of net income, with a net margin of 28.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.